The dose selection and ASPENOVA initiation are material de-risking events for the azenosertib program. The stock should re-rate on the clearer path to accelerated approval. Key catalysts to watch: DENALI Part 2 topline readout (YE 2026) and any interim data from ASPENOVA. Cash runway into late 2027 removes near-term financing risk. Monitor for potential partnership or co-development deals as the program advances.
Price Chart
Executive Summary
Zentalis reported Q1 2026 results with a net loss of $35.4M ($0.50/share), slightly better than the $0.52 consensus. The key catalyst is the selection of the 400mg QD 5:2 dose for azenosertib in Cyclin E1-positive PROC, the first patient dosed in the Phase 3 ASPENOVA confirmatory trial, and the on-track DENALI Part 2 topline readout expected by year-end 2026. Cash of $211.8M provides runway into late 2027, funding execution through these pivotal milestones.
Key Financial Metrics
Key Facts
- Net loss of $35.4M ($0.50/share) for Q1 2026 vs $48.3M ($0.67/share) in Q1 2025 — beat consensus EPS of -$0.52 by 4.5%
- Cash, cash equivalents and marketable securities of $211.8M as of March 31, 2026, providing runway into late 2027
- Selected 400mg QD 5:2 as the pivotal dose for azenosertib monotherapy in Cyclin E1-positive PROC based on DENALI Part 2a interim analysis
- ASPENOVA Phase 3 confirmatory trial first patient dosed in May 2026 — designed to support full approval
- DENALI Part 2 topline readout on track for year-end 2026, with potential to support accelerated approval
- Total operating expenses decreased to $37.9M from $45.6M in Q1 2025, partly due to absence of $7.8M restructuring charge
- R&D expenses increased to $28.7M from $27.2M, driven by advancing DENALI and ASPENOVA trials
- Pre-commercial launch preparedness activities initiated following dose selection
Financial Impact
Net loss improved by $12.9M YoY to $35.4M; cash burn of $34.1M in Q1 2026; EPS beat consensus by $0.02
Risk Factors
- DENALI Part 2 topline data may fail to meet efficacy endpoints required for accelerated approval
- ASPENOVA Phase 3 trial enrollment or results could disappoint, delaying full approval
- Competition from other WEE1 inhibitors or emerging therapies in PROC could limit market opportunity
- Cash burn rate may require additional financing before late 2027 if milestones are delayed
- Safety profile at 400mg dose, while improved, still shows Grade 3+ adverse events including neutropenia (12.7%) and fatigue (12.1%)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001725160-26-000041 |
| Document: zntlq12026corporatedeck.htm | 0001725160-26-000041 |
| Document: zntl-20260512.htm | 0001725160-26-000041 |
| Document: 0001725160-26-000041-index-headers.html | 0001725160-26-000041 |
| Document: 0001725160-26-000041-index.html | 0001725160-26-000041 |
| Document: 0001725160-26-000041.txt | 0001725160-26-000041 |
| 8-K Data (Synthetic) | 0001725160-26-000041 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | 8-K | $3.71 $3.13 | ▲ +15.52% | ▲ +13.54% | $2.52 (+31.98%) |
Aug 14, 2026 7w ago | Press Release | $3.56 $3.50 | ▲ +1.69% | ▼ −0.31% | $2.52 (+29.21%) |
Jun 11, 2026 16w ago | Institutional Cluster | $3.75 $4.88 | ▲ +30.13% | ▲ +28.35% | $2.52 (−32.80%) |
Jun 1, 2026 17w ago | Press Release | $3.95 $4.36 | ▲ +10.25% | ▲ +11.82% | $2.52 (−36.20%) |
May 21, 2026 19w ago | Press Release | $4.06 $3.70 | ▼ −8.87% | ▼ −7.45% | $2.52 (−37.93%) |
May 21, 2026 19w ago | 8-K | $4.06 $3.70 | ▼ −8.87% | ▼ −7.45% | $2.52 (−37.93%) |
May 12, 2026 20w ago | 8-K | $4.28 $3.52 | ▼ −17.76% | ▼ −17.14% | $2.52 (−41.12%) |
May 12, 2026 20w ago | Press Release | $4.28 $3.52 | ▼ −17.76% | ▼ −17.14% | $2.52 (−41.12%) |
Apr 21, 2026 23w ago | Press Release | $3.99 $3.63 | ▼ −9.02% | ▼ −13.94% | $2.52 (−36.84%) |
Apr 17, 2026 24w ago | Press Release | $4.64 $4.09 | ▼ −11.85% | ▼ −17.22% | $2.52 (−45.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access